Gujarat Themis Biosyn Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

2 Patel, Krupesh; Patel, Sachin Dinesh

Analysts

10 Agarwal, Arihant; Arya, Saloni Hemnani; Iyer, Vignesh; Kiran, Hitesh Kumar; Maity, Mithun; Pandey, Nemesh; Parekh, Viraj; Saurabh, Saket; Shah, Nirali; Upadhyay, Harsh

Financials & KPIs

Geographic & Segment Commentary

Fermentation Intermediates (Core Business): Revenue flat over last 4 years due to being sold out; company operated at full capacity with existing customers under long-term contracts, limiting ability to produce APIs without cannibalizing committed intermediate supplies. New 540 KL expanded fermentation capacity begins full-scale production by end of August 2026, enabling both continued intermediate growth and downstream API production for the first time.

MicroBioPharm Japan (MBJ): Wholly-owned acquisition focused on precision fermentation; 60% of revenue is CDMO, 40% proprietary/products; 100% API CDMO with only ~4–5% formulation. Client mix is 60% Japan, 40% outside Japan (Europe/US). All technology platforms except ADCs—peptides, plasmids, enzyme engineering, precision fermentation, immunosuppressants, oncology, anti-infectives—already commercialized with GMP accreditations, with at least one commercially validated product each. Acquisition gives access to established pharma relationships and specialized scientific talent.

Sanofi Brand Portfolio: 13 established anti-TB and anti-infective branded generic products covering 55 countries across Europe, Middle East, and Africa. Currently under-marketed by Sanofi; company plans aggressive go-to-market via existing strong distributors in some markets and new tie-ups in others. Three-year transition service agreement with Sanofi for country-by-country marketing authorization transfer and CMO manufacturing migration; tech transfers expected complete within first year, manufacturing fully under GTBL control within 3 years maximum.

Company-Specific & Strategic Commentary

Transformational Strategy: GTBL repositioning from fermentation intermediate manufacturer to vertically integrated fermentation-led CDMO platform. Strategy combines expanded fermentation infrastructure, downstream API capacity, MBJ technology acquisition, and Sanofi brand portfolio to capture higher value across the pharmaceutical value chain—from intermediates to APIs to finished formulations.

Acquisition Rationale (MBJ + Sanofi): Both acquisitions target steady, non-cyclical businesses; MBJ engaged since ~2.5 years ago viewing it as a 7–8 year capability jump-start in bio-CDDMO competencies. Sanofi acquisition provides forward integration and distributes margins, "securing the bread and butter" of the core business, with significant margin improvement expected via integrating own APIs into the acquired brand supply chain.

Hybrid Power Project: Two-phase hybrid power plant expected to go live—Phase 1 in September 2026, Phase 2 two months later. Will materially reduce power costs (a significant input cost) and further support EBITDA margin expansion.

Merger With Themis Biosyn Withdrawn: Initially pursued fully integrated domestic pharma play with brands, but external strategic review led to clarity that GTBL should focus exclusively on fermentation-based CDMO, avoiding dilution of focus into predominantly domestic-branded businesses.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

API Block Delay & Business Flatness

• Question: Why has API block taken 2 years beyond original FY25 guidance, and why revenues stuck ~₹40 crore for 3 years? (Harsh Upadhyay)
• Answer: API block couldn't start because fermentation capacity was fully contracted to long-term customers; producing APIs would cannibalize committed intermediate sales. New expanded fermentation capacity now enables API production without cannibalization. (Sachin Patel)

Acquisition Financing & Interest Cost

• Question: With ₹3,000 crore acquisitions funded by ₹1,000 crore QIP + ₹2,000 crore debt at ~10%, won't ₹200 crore annual interest burden destroy near-term profitability? (Harsh Upadhyay)
• Answer: Interest rates in target geographies significantly lower than 10%; both businesses cash-flow positive from day one; financing mix being optimized at closing with multiple avenues ready including ₹1,000 crore equity and ~₹450 crore debt plus ₹1,000 crore guarantee from group company. (Sachin Patel)

Merger Withdrawal Rationale

• Question: Why pursue merger with Themis Biosyn in Nov 2024 and withdraw after 6 months? (Harsh Upadhyay)
• Answer: Initial plan was fully integrated domestic pharma with brands; external strategic review clarified GTBL should remain focused exclusively as fermentation-based CDMO; merger would dilute focus into predominantly domestic branded business. (Sachin Patel)

MBJ Technology Commercialization Status

• Question: Which MBJ platforms are commercially validated vs 5-year optionality, and revenue per vertical? (Nirali Shah)
• Answer: All platforms except ADCs commercialized with GMP accreditations and at least one product each—peptides, plasmids, enzyme engineering, precision fermentation, immunosuppressants, oncology, anti-infectives. ADCs patented technology awaiting first CDMO project. Revenue breakdown by vertical not disclosed. (Sachin Patel)

Expanded Capacity Utilization & Customers

• Question: What utilization from additional 540 KL capacity and customer qualification status? (Nirali Shah)
• Answer: New site starts full steam by end of August; fermentation is 0/100—company runs at full scale and sells everything produced; target is all intermediate customers in India and globally. (Sachin Patel)

Sanofi Manufacturing & Transition Timeline

• Question: Who manufactures Sanofi products post-closing, and when fully in-house? (Mithun Maity)
• Answer: 3-year TSA with step-by-step country-by-country transfer of marketing authorizations; manufacturing via existing + new CMOs, some possibly not in India; tech transfers complete within first year though manufacturing migration may take up to 3 years. (Sachin Patel)

MBJ Competitor Landscape & Capabilities

• Question: What specific capabilities and who do we compete against? (Hitesh Kumar Kiran)
• Answer: Broader product category (immunosuppressants, oncology, anti-infectives) plus capabilities in peptides, plasmids (base for DNA/RNA/gene therapy/CAR-T), precision fermentation, enzyme engineering, ADC development. Competitors globally include Lonza, WuXi (China), Anthem Biosciences (India), and a few others—not too many at full fermentation CDMO scale. (Sachin Patel)

Acquisition Digestion Risk & Timeframe

• Question: Given company size, isn't two back-to-back overseas acquisitions spreading management thin with leverage and integration risk? (Hitesh Kumar Kiran)
• Answer: Both businesses historically steady with no major ups/downs—not turnaround situations; MBJ has strong retained management; integration synergies sought via common projects where India-Japan combined advantage comes through, no plan to manage Japan operations directly. Initiation toward MBJ was proactive 2.5 years ago; some synergy projects expected within first year. (Sachin Patel)

Base Business Growth & Asset Turns

• Question: What is 3–5 year vision and how will asset turns play out from new investments? (Viraj Parekh)
• Answer: Gross block ₹62 crores FY23 → ₹435 crores FY26 including CWIP, with ~₹200 crores of that for fermentation + API facilities carrying 1.4–1.5x expected asset turn. Overall base case high-teens revenue growth guided. (Sachin Patel, Krupesh Patel)

Margins of Acquired Businesses & Integration Impact

• Question: Will Sanofi + MBJ be margin dilutive or similar to current GTBL margins? (Hitesh Kumar Kiran)
• Answer: After integration and stabilization, margins should be close to current levels; Sanofi brands have room for both aggressive distribution expansion and margin improvement via replacing Sanofi-sourced APIs with GTBL's own APIs. (Sachin Patel)

Sanofi Brand Marketing & Margin Expansion

• Question: What is marketing approach given Sanofi isn't aggressively promoting these branded generics? (Saket Saurabh)
• Answer: All products are branded generics; some markets already have strong distributors, new tie-ups being established in under-served markets; margin expansion expected from both distribution intensity and API integration into supply chain—opportunities exist on both fronts beyond current already-decent margins. (Sachin Patel)

Optimus Drug Dispute Resolution

• Question: What happened with the dispute and inventory handling? (Harsh Upadhyay)
• Answer: Dispute resolved and business restarting; inventory never an issue as other buyers existed and capacity sold out easily during 6–9 months of non-supply. Company focused on diversifying customer base to sell intermediate to all domestic and export API manufacturers. (Sachin Patel)

Key Takeaway

GTBL reported a solid Q1 FY27 with revenue of ₹43.8 crores (+22.1% YoY) and EBITDA margins expanding 867 bps to 47.5%, driven by volume growth from a fully sold-out base. The quarter is strategically pivotal: the company began commercializing its doubled fermentation capacity (full-scale production from end-August 2026), enabling the long-delayed API block to finally contribute revenue in Q2 onward, with rifapentine, rifaximin, and other molecules in production. Management is executing a transformational strategy toward a fermentation-led CDMO through two major acquisitions—MicroBioPharm Japan (closing end-August 2026, ~₹3,000 crore combined with Sanofi) and the Sanofi brand portfolio (closing in 6–9 months, covering 55 countries). The company guides high-teens revenue growth base case over 3–5 years at 1.4–1.5x asset turns on ~₹200 crore of new capacity investment, with hybrid power savings expected from September 2026. Key risks remain integration complexity of two large overseas acquisitions, ~48% promoter pledge, regulatory approvals across 50+ countries, and the credibility of execution timelines given the 2-year API block delay; investor skepticism persists on digestion capacity and management bandwidth relative to company size.